NASDAQ:GLYC - GlycoMimetics Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $13.00
Forecasted Upside: 470.18 %
Number of Analysts: 3
Breakdown:
0 Sell Ratings
0 Hold Ratings
3 Buy Ratings
0 Strong Buy Ratings

^$2.28 As of 05/7/2021 01:00 AM ET

▼ -0.02 (-0.87%)

1 month | 3 months | 12 months

Get New GlycoMimetics Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for GLYC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GLYC

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$13.00

▲ +470.18% Upside Potential

This price target is based on 3 analysts offering 12 month price targets for GlycoMimetics in the last 3 months. The average price target is $13.00, with a high forecast of $15.00 and a low forecast of $9.00. The average price target represents a 470.18% upside from the last price of $2.28.

Buy

The current consensus among 3 investment analysts is to buy stock in GlycoMimetics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
3 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

11/15/2019

0 strong buy ratings
3 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

2/13/2020

0 strong buy ratings
3 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

5/13/2020

0 strong buy ratings
3 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

8/11/2020

0 strong buy ratings
3 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

11/9/2020

0 strong buy ratings
3 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

2/7/2021

0 strong buy ratings
2 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

4/8/2021

0 strong buy ratings
3 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/8/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
5/3/2021	Stifel Nicolaus	Boost Price Target	Buy	$8.00 ➝ $9.00	High	i
3/10/2021	HC Wainwright	Reiterated Rating	Buy		Medium	i
12/8/2020	Roth Capital	Boost Price Target	Positive ➝ Buy	$9.00 ➝ $15.00	Medium	i
7/31/2020	HC Wainwright	Lower Price Target	Buy	$16.00 ➝ $15.00	Medium	i
5/1/2020	HC Wainwright	Reiterated Rating	Buy	$16.00	High	i
3/27/2020	Cowen	Initiated Coverage	Buy		Low	i Rating by Boris Peaker at Cowen Inc
3/2/2020	HC Wainwright	Lower Price Target	Buy	$18.00 ➝ $16.00	High	i
11/21/2019	Roth Capital	Lower Price Target		$12.00 ➝ $9.00	High	i Rating by Z. Jallah at Roth Capital
11/14/2019	Roth Capital	Initiated Coverage	Buy	$12.00 ➝ $12.00	Medium	i Rating by Z. Jallah at Roth Capital
11/8/2019	HC Wainwright	Reiterated Rating	Buy	$18.00	High	i
11/7/2019	Piper Jaffray Companies	Reiterated Rating	Neutral	$6.00 ➝ $5.00	High	i Rating by Danielle Brill at Piper Jaffray Companies
8/5/2019	HC Wainwright	Lower Price Target	Buy	$23.00 ➝ $18.00	High	i
8/5/2019	Jefferies Financial Group	Downgrade	Buy ➝ Hold		High	i
8/5/2019	SunTrust Banks	Downgrade	Buy ➝ Hold	$23.00 ➝ $5.00	High	i
8/4/2019	Piper Jaffray Companies	Downgrade	Overweight ➝ Neutral	$20.00 ➝ $6.00	High	i
5/3/2019	Cowen	Reiterated Rating	Buy		Medium	i
4/12/2019	HC Wainwright	Reiterated Rating	Buy	$23.00	Low	i Rating by E. White at HC Wainwright
4/12/2019	Piper Jaffray Companies	Initiated Coverage	Overweight	$20.00	High	i
12/18/2018	HC Wainwright	Initiated Coverage	Buy ➝ Buy	$24.00	Low	i Rating by E. White at HC Wainwright
11/5/2018	Roth Capital	Set Price Target	Buy	$35.00	High	i Rating by Jotin Marango at Roth Capital
8/13/2018	Cowen	Reiterated Rating	Buy		Medium	i
8/12/2018	Stifel Nicolaus	Reiterated Rating	Buy	$24.00	Medium	i
3/7/2018	Stifel Nicolaus	Boost Price Target	Buy ➝ Buy	$23.00 ➝ $25.00	Medium	i
2/8/2018	Roth Capital	Set Price Target	Buy	$35.00	Medium	i Rating by Jotin Marango at Roth Capital
12/20/2017	Jefferies Financial Group	Reiterated Rating	Buy	$21.00	Medium	i
12/14/2017	Stifel Nicolaus	Reiterated Rating	Buy	$23.00	Medium	i
12/12/2017	SunTrust Banks	Boost Price Target	Buy	$32.00	High	i Rating by Yatin Suneja at SunTrust Banks, Inc.
12/6/2017	Cowen	Reiterated Rating	Buy		Low	i
10/26/2017	Jefferies Financial Group	Reiterated Rating	Buy	$16.00	N/A	i
10/23/2017	Roth Capital	Initiated Coverage	Buy	$25.00	N/A	i Rating by J. Marango at Roth Capital
10/4/2017	SunTrust Banks	Reiterated Rating	Buy	$21.00	N/A	i Rating by Yatin Suneja at SunTrust Banks, Inc.
8/7/2017	SunTrust Banks	Set Price Target	Buy	$21.00	Low	i
8/4/2017	Stifel Nicolaus	Reiterated Rating	Buy	$13.00 ➝ $17.00	Low	i
6/6/2017	Stifel Nicolaus	Reiterated Rating	Buy	$13.00	High	i
6/6/2017	Jefferies Financial Group	Lower Price Target	Buy	$16.00 ➝ $9.00	High	i
5/28/2017	Cowen	Reiterated Rating	Outperform		Low	i
5/19/2017	Canaccord Genuity	Reiterated Rating	Buy	$12.00	High	i Rating by John Newman at Canaccord Genuity
5/9/2017	Cowen	Reiterated Rating	Buy		Low	i
3/1/2017	Canaccord Genuity	Set Price Target	Buy	$12.00	N/A	i Rating by John Newman at Canaccord Genuity
12/6/2016	Canaccord Genuity	Set Price Target	Buy	$12.00	N/A	i Rating by John Newman at Canaccord Genuity
11/30/2016	SunTrust Banks	Reiterated Rating	Buy		N/A	i Rating by Yatin Suneja at SunTrust Banks, Inc.
8/15/2016	Cowen	Initiated Coverage	Outperform		N/A	i
8/7/2016	Canaccord Genuity	Reiterated Rating	Buy	$12.00	N/A	i Rating by John Newman at Canaccord Genuity
8/5/2016	Jefferies Financial Group	Reiterated Rating	Buy		N/A	i
8/5/2016	Stifel Nicolaus	Boost Price Target	Buy	$13.00 ➝ $15.00	N/A	i
7/26/2016	SunTrust Banks	Initiated Coverage	Buy	$16.00	N/A	i

(Data available from 5/9/2016 forward)

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's drug candidate include rivipansel, a pan-selectin antagonist for the treatment of vaso-occlusive crisis in sickle cell disease. It is also developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as Phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359 to target E-selectin and a chemokine receptors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin; and Galectin-3, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and collaboration and license agreement with Apollomics for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.

Today's Range

Now: $2.28

$2.25

$2.41

50 Day Range

MA: $2.82

$2.30

$3.46

52 Week Range

Now: $2.28

$2.22

$5.19

Volume

836,472 shs

Average Volume

797,279 shs

Market Capitalization

$117.51 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.46

Frequently Asked Questions

What sell-side analysts currently cover shares of GlycoMimetics?

The following Wall Street sell-side analysts have issued research reports on GlycoMimetics in the last twelve months: HC Wainwright, Roth Capital, Stifel Nicolaus, and Zacks Investment Research.
View the latest analyst ratings for GLYC.

What is the current price target for GlycoMimetics?

3 Wall Street analysts have set twelve-month price targets for GlycoMimetics in the last year. Their average twelve-month price target is $13.00, suggesting a possible upside of 470.2%. Roth Capital has the highest price target set, predicting GLYC will reach $15.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $9.00 for GlycoMimetics in the next year.
View the latest price targets for GLYC.

What is the current consensus analyst rating for GlycoMimetics?

GlycoMimetics currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GLYC will outperform the market and that investors should add to their positions of GlycoMimetics.
View the latest ratings for GLYC.

What other companies compete with GlycoMimetics?

Other companies that are similar to GlycoMimetics include GT Biopharma, Viking Therapeutics, Akouos, Applied Therapeutics, Provention Bio, Sesen Bio, AC Immune, Forte Biosciences, MedAvail, Athenex, TherapeuticsMD, Geron, Seelos Therapeutics, Nature's Sunshine Products and Amryt Pharma.

How do I contact GlycoMimetics' investor relations team?

GlycoMimetics' physical mailing address is 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD, 20850. The biotechnology company's listed phone number is 240-243-1201 and its investor relations email address is [email protected] The official website for GlycoMimetics is www.glycomimetics.com.